DNA Synthesis Market (2026-2036)

The growth of this market is mainly driven by the growing demand for synthetic genes and variant libraries in antibody discovery, protein engineering, and artificial intelligence (AI)-driven molecular design; the growth of next-generation sequencing (NGS) and molecular diagnostics, which consume custom primers, probes, adapters, and target enrichment panels; the expansion of synthetic biology for pharmaceuticals, chemicals, agriculture, and materials; and the growth of gene editing, cell and gene therapy, and mRNA research programs that require synthetic templates and constructs. In addition, the declining cost per base of high-throughput synthesis platforms, the maturation of enzymatic synthesis chemistry, the integration of synthesis with protein expression and screening services, and the expansion of biotechnology research capacity in Asia-Pacific are further supporting the growth of this market.

The DNA Synthesis Market, also referred to as the synthetic DNA market, oligonucleotide and gene synthesis market, or custom DNA synthesis market, comprises the services, instruments, and reagents used to produce DNA sequences specified by researchers and companies, without the need for a natural template. The market includes custom oligonucleotide synthesis, such as primers, probes, adapters, and modified oligonucleotides; oligonucleotide pools; gene synthesis, including synthetic genes, gene fragments, codon-optimized constructs, and variant and combinatorial libraries; DNA synthesizer instruments; and synthesis reagents and consumables, such as phosphoramidites, solid supports, and enzymatic synthesis reagents. The market covers products supplied for research, diagnostic, and preclinical development use, and excludes good manufacturing practice (GMP) manufacturing of oligonucleotide and mRNA drug substances for clinical and commercial supply. The market ecosystem extends from synthesis service providers, instrument and reagent manufacturers, and technology developers to academic and research institutes, pharmaceutical and biotechnology companies, diagnostic laboratories and kit manufacturers, contract research organizations (CROs), and synthetic biology and industrial biotechnology companies.

Synthetic DNA is a foundational input to modern biology. Researchers use oligonucleotides in almost every molecular biology experiment, from PCR and sequencing to cloning and gene editing, and synthetic genes allow genetic designs to be built and tested without cloning them from natural sources. As biology becomes more design-driven, with computational models proposing proteins, pathways, and genetic constructs, the ability to produce DNA quickly, accurately, and affordably has become a central enabler of research productivity.

Gene synthesis and libraries represent the fastest-growing area. In its fiscal third quarter of 2026, ended June 30, 2026, Twist Bioscience Corporation reported record revenue of USD 118.4 million, up 23% year over year, with DNA Synthesis and Protein Solutions revenue of USD 56.6 million, up 39%, approximately 369,000 genes shipped compared with approximately 237,000 a year earlier, and products shipped to approximately 2,650 customers, and raised its fiscal 2026 revenue guidance to USD 456-457 million. Pharmaceutical and biotechnology companies use synthetic genes and variant libraries for antibody discovery and optimization, protein engineering, and enzyme design, and the number of sequences tested in each program is rising as computational design improves and as screening becomes more automated.

Oligonucleotides remain the largest product category, used across research, diagnostics, and sequencing. In the second quarter of 2026, Illumina, Inc. reported sequencing consumables revenue of USD 775 million, up 5% year over year, reflecting continued growth in sequencing volumes that use synthetic oligonucleotides for adapters, index sequences, and target enrichment probes. In the second quarter of 2026, Tempus AI, Inc. reported 31% growth in oncology testing volume and 9,000 molecular residual disease tests, illustrating the growth of NGS-based diagnostics that rely on custom synthetic probes and primers. PCR and quantitative PCR assays, NGS target enrichment panels, and gene-editing experiments all require custom oligonucleotides, frequently with modifications such as fluorescent dyes, quenchers, and chemical linkers, and diagnostic kit manufacturers source oligonucleotides as critical raw materials under supply agreements with defined quality specifications.

Genetic medicine and synthetic biology research are expanding demand further. In July 2026, the U.S. Food and Drug Administration (FDA) expanded the approval of CASGEVY, the first CRISPR-based gene-editing therapy, to children aged two years and older with sickle cell disease or transfusion-dependent beta thalassemia. Gene-editing research requires synthetic templates and constructs, cell and gene therapy development uses synthetic genes, promoters, and regulatory elements, and mRNA research requires linear DNA templates for in vitro transcription. Synthetic biology companies use synthetic DNA to engineer microorganisms and cell lines for the production of pharmaceuticals, specialty chemicals, food ingredients, and materials, often testing large numbers of designs in automated facilities.

Synthesis technology continues to advance. Conventional phosphoramidite chemistry, used for several decades, is limited in the length of product it can produce reliably and uses organic solvents and reagents that generate chemical waste. Silicon-based and high-throughput miniaturized platforms have substantially lowered the cost per base and increased the number of sequences that can be produced in parallel. Enzymatic synthesis, developed by companies including DNA Script, Ansa Biotechnologies, and Molecular Assemblies, uses engineered enzymes in aqueous conditions and is intended to produce longer sequences with fewer errors and less solvent use. Providers also compete on digital design and ordering tools that allow customers to upload, validate, and track sequences.

The market includes leading synthesis providers such as Twist Bioscience, Danaher through Integrated DNA Technologies, Thermo Fisher Scientific, Merck KGaA, GenScript Biotech, Azenta through GENEWIZ, Eurofins Scientific through Eurofins Genomics, LGC through LGC Biosearch Technologies, and Kaneka Eurogentec. These companies compete on turnaround time, sequence accuracy and achievable length, cost per base, success rate with complex sequences, manufacturing scale, modification chemistry, quality systems for diagnostic and regulated customers, and the breadth of adjacent protein, antibody, and cell line services that can be bundled with synthesis.

At the same time, the market faces challenges, including the difficulty and cost of producing long, repetitive, and high-GC sequences, error rates that require sequence verification and correction, commoditization and price competition in standard products, variability in academic research funding, and the solvent and waste burden of conventional chemistry. As a result, companies that combine fast turnaround, high success rates for long and complex constructs, scalable low-cost platforms, robust quality systems, and integration with downstream protein and screening services are expected to capture the largest share of growth over the forecast period.